Novo Nordisk to Test GLP-1 Drugs Against Addiction
Novo Nordisk, maker of Ozempic and Wegovy, says they will start testing GLP-1 drugs for use in treating addiction.
The Profit Potential in the Opioid Epidemic
A journal for pharmaceutical investors takes a look at the profit potential in treating opioid use disorders.
Preventing Relapse During Recovery From Opioid Use Disorder
Researchers at the University of Maryland team up to study the genetics of relapse during recovery from opioid use disorder.
The Under Use of Buprenorphine for Opioid Use Disorder
The New York Times Magazine takes a long look at the history of the opioid crisis and the under use of buprenorphine for opioid use disorder.
Sleep and Substance Use Disorder
New studies examine the relationship between sleep and substance use disorder.
Does Ozempic Cause Blindness?
A new study from JAMA Ophthalmology reviews nine cases of sudden vision loss associated with taking GLP-1 drugs.